Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | RB1 positive |
Therapy | Paclitaxel + Palbociclib |
Indication/Tumor Type | breast cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RB1 positive | breast cancer | predicted - sensitive | Paclitaxel + Palbociclib | Phase I | Actionable | In a Phase I trial, alternating sequential treatment with Ibrance (palbociclib) and Taxol (paclitaxel) resulted in a median progression-free survival (mPFS) of 209 days in patients with Rb1-positive breast cancer, with a mPFS of 802 days and a clinical benefit rate of 55.6% (5/9) at the recommended phase II dose (PMID: 30635336; NCT01320592). | 30635336 |
PubMed Id | Reference Title | Details |
---|---|---|
(30635336) | Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer. | Full reference... |